Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)
Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.
Le Lézard4h
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - MRK
The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . Shareholders who purchased shares of MRK ...
Merck KGaA (ETR:MRK) shareholders have earned a 8.1% CAGR over the last five years
For example, the Merck KGaA (ETR:MRK) share price is up 39% in the last five years, slightly above the market return. In comparison, the share price is down 13% in a year. So let's assess the ...
Investing Snacks8h
Merck’s Keytruda Injection Faces Patent Battle With Halozyme
Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...
Merck & Co. (MRK): An Undervalued Wide Moat Stock to Buy According to Analysts
We recently compiled a list of the 12 Undervalued Wide Moat Stocks to Buy According to Analysts. In this article, we are ...
New version of Merck's Keytruda faces possible patent battle, WSJ reports
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...